CGON — CG Oncology Income Statement
0.000.00%
Last trade - 00:00- $1.70bn
- $962.97m
- $1.14m
- 51
- 14
- 14
- 15
Annual income statement for CG Oncology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 10.4 | 0.191 | 0.204 | 1.14 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Total Operating Expenses | 23 | 35.4 | 55.7 | 116 |
| Operating Profit | -12.6 | -35.2 | -55.4 | -115 |
| Total Net Non Operating Interest Income / Expense | ||||
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -12.8 | -35.4 | -48.6 | -88 |
| Net Income After Taxes | -12.8 | -35.4 | -48.6 | -88 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -12.8 | -35.4 | -48.6 | -88 |
| Adjustments to Net Income | ||||
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -18.4 | -43.8 | -67.8 | -88 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.29 | -0.69 | -1.07 | -1.41 |
| Dividends per Share |